RecruitingPhase 2NCT05653635

Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study


Sponsor

Centre Paul Strauss

Enrollment

54 participants

Start Date

Mar 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This French study investigates whether using a special brain imaging scan called PET-DOPA to guide re-irradiation improves outcomes in patients whose glioblastoma (a type of brain tumor) has come back after initial treatment. **You may be eligible if...** - You are over 18 years old - You have a confirmed glioblastoma (WHO grade IV) that has recurred after prior radiation - You have 1 to 3 recurrence sites, each smaller than 35mm - Your overall health and neurological function are adequate - The recurrence is far enough from critical structures like optic nerves and brainstem **You may NOT be eligible if...** - You cannot have an MRI or PET scan - You have a widespread (diffuse) form of glioblastoma - You are pregnant or breastfeeding - You do not speak French - You are not affiliated with the French social security system Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONSimultaneous-integrated boost with IMRT

Simultaneous-integrated boost guided by FDOPA-PET


Locations(2)

CHRU de Nancy

Nancy, De, France

Centre Paul Strauss

Strasbourg, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05653635


Related Trials